Trial Profile

A pivotal randomized study of SurVaxM for patients with newly diagnosed glioblastoma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SVN53-67-M57-KLH peptide vaccine (Primary)
Indications Glioblastoma
Focus Registrational; Therapeutic Use
Sponsors MimiVax

Most Recent Events

18 Nov 2019 According to a MimiVax Media release, MimiVax LLC and Shanghai Fosun Pharmaceutical have entered into a China-exclusive licensing agreement on SurVaxM for glioblastoma treatment in China.
18 Nov 2019 According to a MimiVax Media release, this study is planned in 2020 to be performed at cancer centers across the United States and in China.
31 May 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com